---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-122786"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-12-19T23:59:59+00:00"
generated_at: "2026-05-16T12:34:59.647316+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics FY2025 net loss $62.4M; $1.4M revenue from LYTENAVA launch in Europe

## Summary
- Net loss $62.4M ($1.79/share) vs $75.4M ($4.06/share) prior year; revenue $1.4M from initial EU sales.
- Cash $8.1M at Sept 30, 2025; $14.9M net from ATM after quarter-end; no debt mentioned.
- Expenses fell $4.6M YoY due to lower R&D, partly offset by higher SG&A for European launch.
- FDA PDUFA goal date for ONS-5010 is Dec 31, 2025; awaiting U.S. approval decision.
- LYTENAVA accepted into UK tender framework in Dec 2025; launch expanding to Austria and Netherlands.

## SEC filing metadata
- accession: 0001104659-25-122786
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-12-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/0001104659-25-122786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925122786/tm2533934d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-122786
- JSON: https://secwatch.observer/filing/0001104659-25-122786.json
- Plain text: https://secwatch.observer/filing/0001104659-25-122786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.